STOCK TITAN

Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Atea Pharmaceuticals director Bruno Lucidi reported equity compensation activity centered on stock awards rather than open‑market trades. He exercised 29,600 restricted stock units into Common Stock and held 142,350 Common shares directly afterward. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, all subject to time‑based vesting over the coming year.

Positive

  • None.

Negative

  • None.
Insider Lucidi Bruno
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 29,600 $0.00 --
Grant/Award Restricted Stock Units 26,700 $0.00 --
Grant/Award Stock Option (Right to Buy) 37,700 $0.00 --
Exercise Common Stock 29,600 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Stock Option (Right to Buy) — 37,700 shares (Direct, null); Common Stock — 142,350 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested in full on June 18, 2026. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
RSUs exercised 29,600 shares Restricted stock units converted to Common Stock on June 18, 2026
Direct Common Stock holdings 142,350 shares Shares directly held by Bruno Lucidi after transactions
New stock options granted 37,700 options Right to buy Common Stock, vesting over 12 months
Option exercise price $4.36 per share Conversion or exercise price for 37,700 stock options
New RSUs granted 26,700 units Restricted stock units tied to Atea Common Stock
Option expiration June 17, 2036 Expiration date for the 37,700 stock options
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 4.3600 per share"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vests financial
"The option vests and becomes exercisable in twelve substantially equal monthly installments"
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucidi Bruno

(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026M29,600A$0(1)142,350D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/18/2026M29,600 (2) (2)Common Stock29,600$00D
Restricted Stock Units(1)06/18/2026A26,700 (3) (3)Common Stock26,700$026,700D
Stock Option (Right to Buy)$4.3606/18/2026A37,700 (4)06/17/2036Common Stock37,700$037,700D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. The RSUs vested in full on June 18, 2026.
3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
/s/ Andrea Corcoran, as Attorney-in-Fact for Bruno Lucidi06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Bruno Lucidi report for Atea Pharmaceuticals (AVIR)?

Bruno Lucidi reported equity-related acquisitions only. He exercised 29,600 restricted stock units into Common Stock, received 37,700 stock options, and was granted 26,700 new restricted stock units, all as part of compensation rather than open-market buying or selling.

How many Atea Pharmaceuticals shares does Bruno Lucidi hold after these Form 4 transactions?

After exercising restricted stock units, Bruno Lucidi directly holds 142,350 shares of Atea Pharmaceuticals Common Stock. This figure reflects his updated direct ownership position following the June 18, 2026 transactions reported in the Form 4 filing.

What are the terms of Bruno Lucidi’s new Atea Pharmaceuticals stock options?

Lucidi received 37,700 stock options with a $4.36 exercise price, each relating to one share of Common Stock. The options vest in twelve substantially equal monthly installments after June 18, 2026 and become fully vested on June 18, 2027, subject to continued service.

How do Bruno Lucidi’s new restricted stock units at Atea Pharmaceuticals vest?

He was granted 26,700 restricted stock units, each representing one potential share of Common Stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, assuming he continues serving through that date.

What happened to the 29,600 restricted stock units reported in Bruno Lucidi’s Form 4?

The 29,600 restricted stock units vested in full on June 18, 2026 and were exercised into an equal number of Atea Pharmaceuticals Common shares. Following this vesting and conversion, the RSU balance for that award dropped to zero and his direct share holdings increased.